Sino Biological, Inc. has introduced 4RISE™, an integrated wet-lab validation solution designed to bridge the gap between AI-generated protein designs and experimental confirmation. The platform combines high-throughput expression, a vast target protein library, and multi-dimensional validation to help researchers determine whether AI-designed molecules properly express, bind targets, and exhibit desired biological properties. The announcement was made via NEWMEDIAWIRE.
4RISE™ is built around four core strengths: Rapid, In-Depth, Seamless, and Empirical. Under the Rapid pillar, XPressMAX™ cell-free protein synthesis enables recombinant protein expression in approximately three hours, with success rates exceeding 99% in established workflows. Combined with more than 11,000 ready-to-use target proteins and high-throughput SPR/BLI analysis, applicable workflows can deliver AI-ready binding data in as little as three days. Structured experimental data and API access further support integration into downstream research and optimization pipelines.
The In-Depth component extends beyond binding and kinetic characterization to assess developability and biological function through more than 20 developability assays and molecular and cell-based functional assays. Seamless integration is achieved via complementary cell-free and mammalian expression platforms that accommodate diverse molecule types, alongside antibody production, binding characterization, and functional validation. The Empirical pillar reflects Sino Biological's proven experience with AI-designed molecules, including miniproteins, VHH, scFv, Fab, IgG, enzymes, and cytokines. The company has collaborated with more than 50 AI companies on wet-lab validation.
“AI-driven discovery requires more than computational predictions. Researchers need reliable experimental evidence to evaluate candidates and guide subsequent design decisions,” said Dr. Rob Burgess, Chief Business Officer at Sino Biological US. “4RISE™ combines rapid expression, extensive target resources, and in-depth validation to help researchers move faster and gain deeper insights.”
The launch addresses a critical bottleneck in AI-driven biotherapeutic discovery: while AI can generate protein candidates at unprecedented speed, experimental validation remains essential to confirm expression, binding, and biological activity. By accelerating expression, screening, and data delivery, 4RISE™ helps researchers rapidly identify promising candidates and advance design cycles. This integrated approach could reduce the time and cost associated with traditional validation workflows, potentially accelerating the development of novel therapeutics, vaccines, and diagnostics.
For researchers and AI companies, the platform offers a streamlined path from computational predictions to experimental evidence, with the potential to improve the efficiency of drug discovery pipelines. Sino Biological serves researchers in more than 90 countries and supports basic research, drug discovery, vaccine development, and diagnostics. More information about 4RISE™ high-throughput wet-lab validation services is available at https://www.sinobiological.com/services/htp-platform-for-ai-driven-antibody-discovery, and the company's broader offerings can be found at www.sinobiological.com.
